Exyte completes Pharmaplan integration
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
Owlet’s push comes as parents demand smarter, more dependable nursery tech
The fresh capital will propel Cordance into its first-in-human clinical trial
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Subscribe To Our Newsletter & Stay Updated